[A multicenter comparison of veralipride versus placebo in the vasomotor flushes of menopause. An evaluation of the prolonged effect].
This double-blind study demonstrates in 144 patients that veralipride is more efficient than a placebo in the treatment of a post menopausal hot flashes. After 3 successive treatment periods of 20 days, at a dose of 1 tablet per day, there is a significant reduction in frequency and intensity of hot flashes in the group with veralipride. This effect is prolonged during 3 months after cessation of therapy, although it is progressively less marked. Neuropsychic symptoms are also improved. Clinical and biological tolerance has been excellent.
Boulot
P
P
Service de Gynécologie-Obstétrique, Maternité, Montpellier.
Viala
J L
JL
D000328:Adult; D000368:Aged; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010919:Placebos; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D010919:Placebos; D013469:Sulpiride; C027429:veralipride
Comparaison multicentrique véralipride versus placebo dans les bouffées vasomotrices de la ménopause. Evaluation de la rémanence.